Translations:Discovery and development of angiotensin receptor blockers/39/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 10:25, 28 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Discovery and development of angiotensin receptor blockers)
==Drug comparison and pharmacokinetics==
{| class="wikitable" border="1"
|+ Table 1: Comparison of ARB [[pharmacokinetics]]
|-
! Drug
! Biological half-life [h]
! Protein binding [%]
! Bioavailability [%]
! Renal/hepatic [[Clearance (medicine)|clearance]] [%]
! Food effect
! Daily dosage [mg]
|-
| [[Losartan]]
| 2
| 98.7
| 33
| 10/90
| Minimal
| 50-100
|-
| [[EXP 3174]]
| 6-9
| 99.8
| -
| 50/50
| -
| -
|-
| [[Candesartan]]
| 9
| >99
| 15
| 60/40
| No
| 4-32
|-
| [[Valsartan]]
| 6
| 95
| 25
| 30/70
| 40-50% decreased by
| 80-320
|-
| [[Irbesartan]]
| 11-15
| 90-95
| 70
| 1/99
| No
| 150-300
|-
| [[Telmisartan]]
| 24
| >99
| 42-58
| 1/99
| No
| 40-80
|-
| [[Eprosartan]]
| 5
| 98
| 13
| 30/70
| No
| 400-800
|-
| [[Olmesartan]]
| 14-16
| >99
| 29
| 40/60
| No
| 10-40
|-
| colspan="7" style="text-align: center;" |Sources:
|}

Drug comparison and pharmacokinetics

Table 1: Comparison of ARB pharmacokinetics
Drug Biological half-life [h] Protein binding [%] Bioavailability [%] Renal/hepatic clearance [%] Food effect Daily dosage [mg]
Losartan 2 98.7 33 10/90 Minimal 50-100
EXP 3174 6-9 99.8 - 50/50 - -
Candesartan 9 >99 15 60/40 No 4-32
Valsartan 6 95 25 30/70 40-50% decreased by 80-320
Irbesartan 11-15 90-95 70 1/99 No 150-300
Telmisartan 24 >99 42-58 1/99 No 40-80
Eprosartan 5 98 13 30/70 No 400-800
Olmesartan 14-16 >99 29 40/60 No 10-40
Sources:
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/39/en&oldid=131496"